Wound care formulations with clinically effective ingredient content

Abstract

The disclosed wound-healing formulation adds ingredients from the group consisting of camphor, menthol and eucalyptus to known silver sulfadiazine-based formulations, or to known silver sulfadiazine-and-urogastrone-based formulations, preferably for the topical treatment of skin wounds such as cuts, burns, surgical wounds, etc. Preferred embodiments are in cream form. The disclosed formulation shows unexpected and startling improvement in wound healing rates over expected healing rates using the known silver sulfadiazine-based or silver sulfadiazine-and-urogastrone-based formulations alone.

I claim: 
     
         1 . A topical formulation, comprising:
 (a) at least about 1% silver sulfadiazine;   (b) at least about 0.001% urogastrone; and   (c) at least one ingredient selected from the group consisting of:
 (1) camphor in a clinically effective concentration for the topical formulation to increase rate of wound healing over placebo; 
 (2) menthol in a clinically effective concentration for the topical formulation to increase rate of wound healing over placebo; and 
 (3)  eucalyptus  in a clinically effective concentration for the topical formulation to increase rate of wound healing over placebo. 
   
     
     
         2 . A topical formulation, comprising:
 (a) at least about 1% silver sulfadiazine;   (b) at least about 0.001% urogastrone; and   (c) at least two ingredients selected from the group consisting of:
 (1) camphor in a clinically effective concentration for the topical formulation to increase rate of wound healing over placebo; 
 (2) menthol in a clinically effective concentration for the topical formulation to increase rate of wound healing over placebo; and 
 (3)  eucalyptus  in a clinically effective concentration for the topical formulation to increase rate of wound healing over placebo. 
   
     
     
         3 . A topical formulation, comprising:
 (a) at least about 1% silver sulfadiazine;   (b) at least about 0.001% urogastrone;   (c) camphor in a clinically effective concentration for the topical formulation to increase rate of wound healing over placebo;   (d) menthol in a clinically effective concentration for the topical formulation to increase rate of wound healing over placebo; and   (e)  eucalyptus  in a clinically effective concentration for the topical formulation to increase rate of wound healing over placebo.